Biogen Inc.
BIIB
Key stats
- Open
- 255.00
- Day high
- 255.05
- Day low
- 250.43
- Previous close
- 253.40
- Volume
- 792.5K
- VWAP
- 251.70
- 52-week high
- 261.00
- 52-week low
- 158.05
- Market cap
- 37.46B
- Shares out
- 147.82M
- Employees
- 7,500
- Listed
- 1991
About Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CAMBRIDGE, MA · biogen.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 362
- Put open interest
- 916
- Put/call
- 2.53
- At-the-money IV
- 50.8%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 230 put | 0.10 | Nov 10, 10:02 AM | 30 | 290 | 119.3% |
| 267.50 call | 0.15 | Nov 12, 1:19 PM | 26 | 16 | 82.1% |
| 242.50 put | 1.00 | Nov 9, 10:42 AM | 20 | 23 | 80.0% |
| 270 call | 0.05 | Nov 12, 1:19 PM | 11 | 28 | 129.4% |
| 225 put | 0.34 | Nov 9, 9:36 AM | 10 | 44 | 118.2% |
| 250 call | 3.00 | Nov 12, 2:49 PM | 8 | 21 | 51.7% |
Quarterly results
Massive · Oct 28, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $2.80B | $2.74B | $2.48B | $2.28B |
| Gross profit | $2.06B | $1.96B | $1.82B | $1.78B |
| Operating income | $128.80M | $150.90M | $397.40M | $98.40M |
| Net income | −$20.60M | $97.50M | $319.50M | −$48.90M |
| Diluted EPS | -0.14 | 0.66 | 2.15 | -0.33 |
| Operating cash flow | $640.80M | $448.90M | $645.50M | $511.90M |
| Assets | $32.05B | $32.09B | $29.48B | $29.44B |
| Liabilities | $13.13B | $13.24B | $10.83B | $11.18B |
| Equity | $18.92B | $18.85B | $18.65B | $18.26B |
Technicals
Massive · Nov 12, 2026- 50-day average232.77
- 200-day average204.77
- RSI (14 days)56.8
Short interest
Massive · Oct 30, 2026- Oct 30, 20265.45M shares · 4.0 days to cover
- Oct 15, 20265.50M shares · 4.4 days to cover
- Sep 30, 20265.97M shares · 4.9 days to cover
- Sep 15, 20265.82M shares · 7.6 days to cover
Related companies
MassiveNews coverage
No stories about Biogen Inc. right now.